Abstract
BackgroundDengue is an important mosquito-borne disease. There is currently only one licensed vaccine for dengue prevention. The vaccine provides higher efficacy in pre-vaccination dengue-seropositive persons but a higher risk of subsequent more severe dengue in dengue-seronegative persons. It is recommended that the dengue vaccine may be given in dengue-seropositive individuals or as mass vaccination without individual pre-vaccination screening in areas where the dengue seroprevalence is > 80% in children aged 9 years. We evaluated a dengue specific immunoglobulin G monoclonal antibody-based capture enzyme-linked immunosorbent assay (MAb-ELISA) in the diagnosis of previous dengue infection using serum samples from the cohort study in Ratchaburi Province, Thailand.MethodsThe MAb-ELISA was compared to 70% plaque reduction neutralization test (PRNT70) in 453 serum samples from children aged 3–11 years in Ratchaburi Province, Thailand.ResultsThe sensitivity and specificity of MAb-ELISA at the positive to negative (P/N) ratio cut-off level of > 3 were both 0.91 in the diagnosis of previous dengue infection, compared to PRNT70. The false positivity was mainly in Japanese encephalitis (JE) seropositive subjects.ConclusionsThis research provides evidence that MAb-ELISA is useful for dengue seroprevalence study and dengue pre-vaccination screening. JE seropositivity was the major cause of false positive result in the study population.
Highlights
To the best of our knowledge, there has been no study primarily aiming to evaluate the accuracy of the dengue specific immunoglobulin G (IgG) monoclonal antibody-based capture enzyme-linked immunosorbent assay (MAb-ELISA) in the assessment of dengue serostatus
The objective of this report was to evaluate the sensitivity and specificity of MAb-ELISA compared to 70% plaque reduction neutralization test (PRNT70) for the assessment of dengue serostatus
In order to compare the performance of the two tests, a receiver operating characteristic (ROC) curve was constructed and an appropriate cut-off level was identified with optimal sensitivity and specificity for the diagnosis of previous dengue infection
Summary
We evaluated a dengue specific immunoglobulin G monoclonal antibody-based capture enzyme-linked immunosorbent assay (MAb-ELISA) in the diagnosis of previous dengue infection using serum samples from the cohort study in Ratchaburi Province, Thailand. There has been no specific treatment for dengue but currently, one dengue vaccine is licensed This tetravalent chimeric yellow fever-dengue vaccine (Dengvaxia®) has been approved for the prevention of dengue in children and adults aged 9–45 years. Other tests that can be used in assessing the existence of dengue antibody include dengue NS1 antibody enzyme-linked immunosorbent assay (ELISA) [11], dengue-specific antibody ELISA [12] and hemagglutination inhibition test. To the best of our knowledge, there has been no study primarily aiming to evaluate the accuracy of the dengue specific immunoglobulin G (IgG) monoclonal antibody-based capture enzyme-linked immunosorbent assay (MAb-ELISA) in the assessment of dengue serostatus
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
